- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03354728
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant
A Phase 1/2 Clinical Study to Evaluate the Optimal Dose and the Protective Effect of CMV-MVA Triplex Vaccine in Pediatric Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To investigate the optimal dose of multi-antigen CMV-modified vaccinia ankara vaccine (Triplex) in CMV-positive pediatric patients receiving human leukocyte antigen (HLA) matched, mismatched, or haploid-identical hematopoietic cell transplantation (HCT). (Phase I) II. To evaluate the safety profile of Triplex in this patient population. (Phase I) III. To determine if Triplex reduces the frequency of CMV events when compared to historical data. (Phase II)
SECONDARY OBJECTIVES:
I. To characterize CMV reactivation and disease by assessing: time to CMV reactivation, duration of viremia, recurrence of viremia, incidence of late CMV viremia/disease (defined as > 100 days and =< 365 days post HCT), use of anti-viral drugs triggered by rising CMV viremia or viremia >= 3750 IU/mL, cumulative number of CMV specific antiviral treatment days.
II. To evaluate the impact of Triplex on transplant related outcomes by assessing the incidence of acute and chronic graft versus host disease (GVHD), relapse, non-relapse mortality (NRM), all-cause mortality, infections.
III. To investigate the impact of Triplex on cellular immunity by investigating: the level, function and kinetics of CMV-specific T-cell immunity, the changes in adaptive natural killer (NK) cell population and highly cytotoxic memory NKG2C+ NK cells, and changes in GVHD biomarkers.
OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.
Patients receive multi-antigen CMV-modified vaccinia ankara vaccine intramuscularly (IM) on days 28 and 56 post-HCT.
After completion of study treatment, patients are followed up for up to 270 or 365 days.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope Medical Center
-
Contact:
- Anna B. Pawlowska
- Phone Number: 626-301-8442
- Email: apawlows@coh.org
-
Principal Investigator:
- Anna B. Pawlowska
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All subjects (or their guardians) must have the ability to understand and the willingness to sign a written informed consent; age appropriate assent will be obtained per institutional guidelines; to allow non-English patients to participate in this study, bilingual health services will be provided in the appropriate language when feasible
- Participant must be willing to comply with study and/or follow-up procedures, including willingness to be followed for one year post-HCT
- Planned allogenic (allo)-HCT, with 9/10 or 10/10 (A, B, C, DRB1, DQB1) high/intermediate resolution HLA donor allele matching and with no T-cell depletion of graft
- Planned related HCT with molecular 3/6 HLA donor allele matching (haploidentical) (for phase I only)
- CMV seropositive at the time of HCT
- Conditioning and immunosuppressive regimens according to institutional guidelines are permitted
- Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration
- Seronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV); if hepatitis B virus (HBV) core seropositive, absence of HBV deoxyribonucleic acid (DNA) within 2 months of registration
- Agreement by females of childbearing potential and sexually active males to use an effective method of contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for up to 90 days post-HCT; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
Exclusion Criteria:
- TRANSPLANT RELATED CRITERIA: Patients undergoing cord blood transplant (CB-HCT)
- Any prior investigational CMV vaccine
- Anti-CMV therapy in the last 6 months
- Live attenuated vaccines
- Medically indicated subunit (Engerix-B for HBV; Gardasil for human papillomavirus [HPV]) or killed vaccine (e.g. influenza, pneumococcal)
- Allergy treatment with antigens injections
- Alemtuzumab, cyclophosphamide, ATG or any equivalent in vivo T-cell depleting agent; Note: Pre-transplant ATG is permitted
- Antiviral medications with known therapeutic effects on CMV such as ganciclovir (GCV)/valine (VAL), FOS, Cidofovir, CMX-001, maribavir; acyclovir has no known therapeutic efficacy against CMV and is allowable as standard of care to prevent herpes simplex virus (HSV)
- Prophylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment; intravenous immunoglobulin therapy (IVIG) is allowed
- Other investigational product-concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibited
- Other medications that might interfere with the evaluation of the investigational product
- Patients with congenital immune deficiency
- Patients with active autoimmune conditions requiring systemic immunosuppressive therapy within the previous 5 years are not eligible, the exception to this is patients with aplastic anemia, who are eligible
- Pregnant women and women who are lactating; CMV-MVA Triplex risks to pregnant women are unknown; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the administered vaccine, also breastfeeding should be discontinued if the mother is enrolled on this study
- Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., social/psychological issues, etc
- Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issue related to feasibility/logistics)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Supportive Care (multi-antigen CMV-modified vaccinia ankara)
Patients receive multi-antigen CMV-modified vaccinia ankara vaccine IM on days 28 and 56 post-HCT.
|
Correlative studies
Given IM
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Optimal dose (Phase I)
Time Frame: Up to 1 year
|
Up to 1 year
|
|
Incidence of adverse events (Phase I)
Time Frame: Up to 1 year
|
Adverse events will be characterized using the descriptions and grading scales according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
|
Up to 1 year
|
Cytomegalovirus (CMV) events (reactivation >= 1250 IU/mL), or viremia treated by anti-viral therapy, or detection of CMV by histology (Phase II)
Time Frame: Prior to day 100 post-hematopoietic cell transplantation (HCT) or viremia treated by anti-viral therapy, or detection of CMV by histology
|
Will be assessed with exact 90% confidence bounds.
|
Prior to day 100 post-hematopoietic cell transplantation (HCT) or viremia treated by anti-viral therapy, or detection of CMV by histology
|
Non-relapse mortality
Time Frame: At 100 days post-HCT
|
Will be compared to historical controls at the final analysis, and a 90% lower confidence bound on the difference in 12-month event free survival will be produced.
|
At 100 days post-HCT
|
Severe (grade 3-4) acute graft versus host disease (aGVHD)
Time Frame: Within 2 weeks from each vaccination
|
Within 2 weeks from each vaccination
|
|
Incidence of grade 3-4 adverse events
Time Frame: Within 2 weeks from each vaccination
|
Will be graded per CTCAE version 4.0.
|
Within 2 weeks from each vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time-to viremia
Time Frame: Number of days from transplant to the date of > 1250 IU/mL, assessed up to 1 year
|
Number of days from transplant to the date of > 1250 IU/mL, assessed up to 1 year
|
|
Duration of viremia
Time Frame: Up to 1 year
|
Up to 1 year
|
|
Incidence of late CMV viremia
Time Frame: > 100 and =< 365 days post-HCT
|
> 100 and =< 365 days post-HCT
|
|
Use of antiviral drugs (triggered by rising CMV viremia or viremia >= 3,750 IU/ml)
Time Frame: Up to 1 year, rising CMV viremia or viremia >= 3,705
|
Up to 1 year, rising CMV viremia or viremia >= 3,705
|
|
Cumulative number of CMV specific antiviral treatment days
Time Frame: Up to 1 year
|
Up to 1 year
|
|
Time to engraftment
Time Frame: Up to 1 year
|
Up to 1 year
|
|
Incidence of acute graft versus host disease (aGVHD)
Time Frame: Up to 1 year
|
Up to 1 year
|
|
Chronic GVHD (cGVHD)
Time Frame: Up to 1 year
|
Up to 1 year
|
|
Relapse defined by bone marrow and/or imaging studies
Time Frame: Up to 1 year
|
Up to 1 year
|
|
Non-relapse mortality
Time Frame: Up to 1 year
|
Up to 1 year
|
|
All-cause mortality
Time Frame: Up to 1 year
|
Up to 1 year
|
|
Infections
Time Frame: Up to 1 year
|
Up to 1 year
|
|
Levels of CMV-specific T cell immunity
Time Frame: Up to 1 year post-HCT
|
Will be combined with immunophenotyping and functional studies.
The data analysis for estimating the effect of vaccination on cellular immunity will necessarily be more exploratory in nature.
The longitudinal CMV-specific cellular assay data will be modeled on a logarithmic scale, using a generalized estimating equation approach to accommodate the stochastic dependence through time.
This produces an estimated multiplicative effect of vaccination, qualified by a valid estimate of variability.
|
Up to 1 year post-HCT
|
Kinetics of CMV-specific T cell immunity
Time Frame: Up to 1 year post-HCT
|
The data analysis for estimating the effect of vaccination on cellular immunity will necessarily be more exploratory in nature.
The longitudinal CMV-specific cellular assay data will be modeled on a logarithmic scale, using a generalized estimating equation approach to accommodate the stochastic dependence through time.
This produces an estimated multiplicative effect of vaccination, qualified by a valid estimate of variability.
|
Up to 1 year post-HCT
|
Natural killer (NK) phenotype
Time Frame: Up to 1 year post-HCT
|
The data analysis for estimating the effect of vaccination on cellular immunity will necessarily be more exploratory in nature.
The longitudinal CMV-specific cellular assay data will be modeled on a logarithmic scale.
|
Up to 1 year post-HCT
|
NK function (cytotoxicity and cytokine production)
Time Frame: Up to 1 year post-HCT
|
The data analysis for estimating the effect of vaccination on cellular immunity will necessarily be more exploratory in nature.
The longitudinal CMV-specific cellular assay data will be modeled on a logarithmic scale, using a generalized estimating equation approach to accommodate the stochastic dependence through time.
This produces an estimated multiplicative effect of vaccination, qualified by a valid estimate of variability.
|
Up to 1 year post-HCT
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Anna Pawlowska, City of Hope Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17236 (Other Identifier: City of Hope Comprehensive Cancer Center)
- NCI-2017-02046 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematopoietic Cell Transplant Recipient
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic Cell Transplantation Recipient | Bone Marrow Transplantation Recipient | Cord Blood Transplant RecipientUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMalignant Neoplasm | Allogeneic Hematopoietic Stem Cell Transplant Recipient | DonorUnited States
-
Laura JohnstonNational Institutes of Health (NIH)CompletedGraft Versus Host Disease | Allogeneic Hematopoietic Cell Transplant RecipientUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Allogeneic Hematopoietic Stem Cell Transplant RecipientUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingAllogeneic Hematopoietic Stem Cell Transplantation RecipientUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityAvailableMalignant Neoplasm | Hematopoietic Cell Transplantation Recipient | Benign Neoplasm | Bone Marrow Transplantation RecipientUnited States
-
University of MichiganHoffmann-La RocheCompletedKidney Transplant Recipient | Heart Transplant RecipientUnited States
-
University of Social Sciences and Humanities, WarsawNational Science Centre, PolandNot yet recruitingHematopoietic Cell Transplantation Recipient | Acceptance and Commitment TherapyPoland
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Allogeneic Hematopoietic Stem Cell Transplant RecipientUnited States
-
Wake Forest University Health SciencesCompletedHematopoietic Cell TransplantUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States